Analyzing Profound Medical (NASDAQ:PROF) and Spectral AI (NASDAQ:MDAI)

Spectral AI (NASDAQ:MDAI) and Profound Medical (NASDAQ:PROF) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, earnings, profitability and institutional ownership.

Profitability

This table compares Spectral AI and Profound Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spectral AI	-69.27%	N/A	-79.96%
Profound Medical	-171.57%	-63.03%	-51.24%

Valuation and Earnings

This table compares Spectral AI and Profound Medical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectral AI	$19.65 million	2.65	-$7.57 million	($0.53)	-3.08
Profound Medical	$16.10 million	15.70	-$42.57 million	($0.98)	-7.10

Spectral AI has higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than Spectral AI, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Spectral AI has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Profound Medical has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500.

Institutional & Insider Ownership

67.1% of Spectral AI shares are owned by institutional investors. Comparatively, 47.9% of Profound Medical shares are owned by institutional investors. 13.7% of Spectral AI shares are owned by insiders. Comparatively, 1.5% of Profound Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Spectral AI and Profound Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	1	0	1	1	2.67
Profound Medical	1	0	1	1	2.67

Spectral AI currently has a consensus target price of $4.00, suggesting a potential upside of 144.65%. Profound Medical has a consensus target price of $11.50, suggesting a potential upside of 65.35%. Given Spectral AI’s higher probable upside, research analysts clearly believe Spectral AI is more favorable than Profound Medical.

Summary

Spectral AI beats Profound Medical on 10 of the 12 factors compared between the two stocks.

About Spectral AI

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.